JP2018524390A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018524390A5 JP2018524390A5 JP2018503191A JP2018503191A JP2018524390A5 JP 2018524390 A5 JP2018524390 A5 JP 2018524390A5 JP 2018503191 A JP2018503191 A JP 2018503191A JP 2018503191 A JP2018503191 A JP 2018503191A JP 2018524390 A5 JP2018524390 A5 JP 2018524390A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- group
- acceptable salt
- hydroxyl
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2015084893 | 2015-07-23 | ||
| CNPCT/CN2015/084893 | 2015-07-23 | ||
| PCT/CN2016/090962 WO2017012576A1 (en) | 2015-07-23 | 2016-07-22 | Compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018524390A JP2018524390A (ja) | 2018-08-30 |
| JP2018524390A5 true JP2018524390A5 (enExample) | 2019-08-29 |
| JP6746679B2 JP6746679B2 (ja) | 2020-08-26 |
Family
ID=57833742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018503191A Expired - Fee Related JP6746679B2 (ja) | 2015-07-23 | 2016-07-22 | 化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10975081B2 (enExample) |
| EP (1) | EP3325449B1 (enExample) |
| JP (1) | JP6746679B2 (enExample) |
| KR (1) | KR20180030201A (enExample) |
| CN (1) | CN108137510B (enExample) |
| AU (1) | AU2016295604B2 (enExample) |
| BR (1) | BR112018001303A2 (enExample) |
| CA (1) | CA2993269A1 (enExample) |
| ES (1) | ES2862188T3 (enExample) |
| RU (1) | RU2725616C2 (enExample) |
| WO (1) | WO2017012576A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019015252A2 (pt) * | 2017-01-25 | 2020-04-14 | Glaxosmithkline Ip Dev Ltd | compostos |
| EP3573975A4 (en) * | 2017-01-25 | 2020-08-12 | GlaxoSmithKline Intellectual Property Management Limited | LINKS |
| BR112019015314A2 (pt) | 2017-01-25 | 2020-05-19 | Glaxosmithkline Ip Dev Ltd | compostos para inibir a atividade da quinase lrrk2 |
| CA3050156A1 (en) * | 2017-01-25 | 2018-08-02 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
| US20210130339A1 (en) * | 2017-01-25 | 2021-05-06 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
| CN106866547B (zh) * | 2017-03-15 | 2020-11-10 | 江苏省农用激素工程技术研究中心有限公司 | 2-乙氧基-4,6-二氯嘧啶的合成方法 |
| WO2019046316A1 (en) * | 2017-08-28 | 2019-03-07 | Acurastem Inc. | PIKFYVE KINASE INHIBITORS |
| US20210261553A1 (en) * | 2018-05-15 | 2021-08-26 | E-Scape Bio, Inc. | Fused tetrazoles as lrrk2 inhibitors |
| KR20190131981A (ko) * | 2018-05-18 | 2019-11-27 | 재단법인 대구경북첨단의료산업진흥재단 | 외상성 뇌손상 또는 뇌졸중의 예방 또는 치료용 약학적 조성물 |
| TWI833770B (zh) | 2018-06-27 | 2024-03-01 | 美商Ionis製藥公司 | 用於減少 lrrk2 表現之化合物及方法 |
| WO2020092136A1 (en) * | 2018-10-31 | 2020-05-07 | Merck Sharp & Dohme Corp. | N-heteroaryl indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
| BR112021018481A2 (pt) | 2019-03-27 | 2021-11-23 | Curasen Therapeutics Inc | Agonista adrenérgico beta e métodos para usar o mesmo |
| WO2020247298A2 (en) | 2019-06-06 | 2020-12-10 | Merck Sharp & Dohme Corp. | 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
| TW202525783A (zh) * | 2019-07-01 | 2025-07-01 | 美商古拉森療法公司 | β腎上腺素激動劑及其使用方法 |
| CN114450274A (zh) | 2019-07-11 | 2022-05-06 | 伊斯凯普生物公司 | 作为lrrk2抑制剂的吲唑及氮杂吲唑 |
| WO2021163727A1 (en) * | 2020-02-11 | 2021-08-19 | AcuraStem Incorporated | Pikfyve kinase inhibitors |
| WO2021178780A1 (en) * | 2020-03-06 | 2021-09-10 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as lrrk2 inhibitors |
| WO2021216973A1 (en) * | 2020-04-24 | 2021-10-28 | The Regents Of The University Of California | Nurr1 receptor modulators and uses thereof |
| WO2022155419A1 (en) * | 2021-01-15 | 2022-07-21 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as lrrk2 inhibitors |
| WO2023073013A1 (en) | 2021-10-27 | 2023-05-04 | H. Lundbeck A/S | Lrrk2 inhibitors |
| WO2023076404A1 (en) | 2021-10-27 | 2023-05-04 | Aria Pharmaceuticals, Inc. | Methods for treating systemic lupus erythematosus |
| AR130483A1 (es) | 2022-09-15 | 2024-12-11 | H Lundbeck As | Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2) |
| WO2025201511A1 (zh) * | 2024-03-29 | 2025-10-02 | 上海京新生物医药有限公司 | 吲唑衍生物及其制备方法与应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1799673A1 (en) * | 2004-10-15 | 2007-06-27 | Memory Pharmaceuticals Corporation | Pyrazole derivatives as phosphodiesterase 4 inhibitors |
| AR051596A1 (es) | 2004-10-26 | 2007-01-24 | Irm Llc | Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios |
| EP2298731A4 (en) * | 2008-06-25 | 2011-09-21 | Takeda Pharmaceutical | AMIDE COMPOUND |
| WO2011106168A1 (en) | 2010-02-24 | 2011-09-01 | Dcam Pharma Inc | Purine compounds for treating autoimmune and demyelinating diseases |
| GB201008134D0 (en) * | 2010-05-14 | 2010-06-30 | Medical Res Council Technology | Compounds |
| WO2012009258A2 (en) * | 2010-07-13 | 2012-01-19 | Edward Roberts | Peptidomimetic galanin receptor modulators |
| EP2489663A1 (en) * | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Compounds as syk kinase inhibitors |
| CA2871388A1 (en) * | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | 5-azaindazole compounds and methods of use |
| WO2014134772A1 (en) | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| WO2014134774A1 (en) * | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| WO2015099196A1 (en) * | 2013-12-26 | 2015-07-02 | Takeda Pharmaceutical Company Limited | 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors |
| WO2016036586A1 (en) * | 2014-09-03 | 2016-03-10 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
-
2016
- 2016-07-22 KR KR1020187004848A patent/KR20180030201A/ko not_active Ceased
- 2016-07-22 JP JP2018503191A patent/JP6746679B2/ja not_active Expired - Fee Related
- 2016-07-22 US US15/746,817 patent/US10975081B2/en not_active Expired - Fee Related
- 2016-07-22 BR BR112018001303A patent/BR112018001303A2/pt not_active IP Right Cessation
- 2016-07-22 CN CN201680054465.2A patent/CN108137510B/zh not_active Expired - Fee Related
- 2016-07-22 CA CA2993269A patent/CA2993269A1/en not_active Abandoned
- 2016-07-22 RU RU2018106453A patent/RU2725616C2/ru active
- 2016-07-22 WO PCT/CN2016/090962 patent/WO2017012576A1/en not_active Ceased
- 2016-07-22 AU AU2016295604A patent/AU2016295604B2/en not_active Ceased
- 2016-07-22 EP EP16827267.2A patent/EP3325449B1/en active Active
- 2016-07-22 ES ES16827267T patent/ES2862188T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018106453A (ru) | Соединения | |
| JP2016506960A5 (enExample) | ||
| JP2017504631A5 (enExample) | ||
| JP2016530259A5 (enExample) | ||
| JP2016515561A5 (enExample) | ||
| JP2019509276A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| CY1120342T1 (el) | Ανταγωνιστης πολυκυκλικου lpa1 και χρησεις εξ' αυτου | |
| JP2016540742A5 (enExample) | ||
| JP2020502092A5 (enExample) | ||
| JP2016530283A5 (enExample) | ||
| JP2018502877A5 (enExample) | ||
| JP2016506962A5 (enExample) | ||
| JP2016515560A5 (enExample) | ||
| JP2016040288A5 (enExample) | ||
| JP2012513416A5 (enExample) | ||
| JP2015500843A5 (enExample) | ||
| PH12021551257A1 (en) | Cyclic pantetheine derivatives and uses thereof | |
| MX2025000126A (es) | Esteroides neuroactivos alfa.-hidroxi-17.beta.-amida y composiciones de los mismos | |
| JP2016506961A5 (enExample) | ||
| JP2015537020A5 (enExample) | ||
| JP2016506935A5 (enExample) | ||
| JP2013509392A5 (enExample) | ||
| JP2015504091A5 (enExample) |